A Study to Assess New Formulations of TEV-56286

Inclusion Criteria:

• Body mass index (BMI) between 18.5 kg/m2 to 32.0 kg/m2 (inclusive)

• Females of childbearing potential agree to take appropriate measures to preventpregnancy during the study

• Males who do not have a documented vasectomy or are not congenitally sterile mustagree to abstinence or use of barrier method with spermicide with female partner.Male participant who is having sexual intercourse with a woman of childbearingpotential who is not currently pregnant will be advised of her requirement to use anadditional highly effective contraceptive method

• NOTE - Additional criteria apply, please contact the investigator for moreinformation

Exclusion Criteria:

• Participation in another clinical trial simultaneously

• Females who are lactating, breastfeeding, or intends to become pregnant over thecourse of the study

• History of alcohol, drug or any other substance, abuse, addiction or dependence inthe last 12 months (except for caffeine)

• Major trauma or surgery in the 2 months before screening or at any time betweenscreening and the first dose of IMP, or surgery scheduled during the study orfollow-up period

• Donated blood or blood products (eg, white blood cells [WBCs], platelets, etc.)within the 60 days before screening, or has donated blood or blood products at leasttwice within the 6 months before screening, or has donated plasma within 7 days ofthe screening visit or has received blood or blood products in the 6 weeks beforescreening

• Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, or long QT syndrome, or a personalhistory of syncope, or previous personal treatment for high blood pressure

• NOTE - Additional criteria apply, please contact the investigator for moreinformation